PT2358355E - Composição farmacêutica de um inibidor potente de vhc para administração oral - Google Patents
Composição farmacêutica de um inibidor potente de vhc para administração oral Download PDFInfo
- Publication number
- PT2358355E PT2358355E PT97603955T PT09760395T PT2358355E PT 2358355 E PT2358355 E PT 2358355E PT 97603955 T PT97603955 T PT 97603955T PT 09760395 T PT09760395 T PT 09760395T PT 2358355 E PT2358355 E PT 2358355E
- Authority
- PT
- Portugal
- Prior art keywords
- pharmaceutical composition
- oral administration
- hcv inhibitor
- potent hcv
- potent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11678908P | 2008-11-21 | 2008-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2358355E true PT2358355E (pt) | 2014-01-08 |
Family
ID=41650279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT97603955T PT2358355E (pt) | 2008-11-21 | 2009-11-18 | Composição farmacêutica de um inibidor potente de vhc para administração oral |
Country Status (35)
Country | Link |
---|---|
US (2) | US20120101049A1 (pt) |
EP (1) | EP2358355B1 (pt) |
JP (1) | JP5553839B2 (pt) |
KR (1) | KR20110087297A (pt) |
CN (1) | CN102223875A (pt) |
AR (1) | AR074391A1 (pt) |
AU (1) | AU2009316755B2 (pt) |
BR (1) | BRPI0921070A2 (pt) |
CA (1) | CA2738732A1 (pt) |
CL (1) | CL2011000878A1 (pt) |
CO (1) | CO6361900A2 (pt) |
CY (1) | CY1114892T1 (pt) |
DK (1) | DK2358355T3 (pt) |
EA (1) | EA022272B1 (pt) |
EC (1) | ECSP11011065A (pt) |
ES (1) | ES2445516T3 (pt) |
HR (1) | HRP20140097T1 (pt) |
IL (1) | IL211832A (pt) |
MA (1) | MA32812B1 (pt) |
ME (1) | ME01614B (pt) |
MX (1) | MX2011005151A (pt) |
MY (1) | MY155402A (pt) |
NZ (1) | NZ592383A (pt) |
PE (1) | PE20120032A1 (pt) |
PL (1) | PL2358355T3 (pt) |
PT (1) | PT2358355E (pt) |
RS (1) | RS53121B (pt) |
SG (1) | SG171771A1 (pt) |
SI (1) | SI2358355T1 (pt) |
TN (1) | TN2011000258A1 (pt) |
TW (1) | TWI469801B (pt) |
UA (1) | UA105777C2 (pt) |
UY (1) | UY32252A (pt) |
WO (1) | WO2010059667A1 (pt) |
ZA (1) | ZA201102029B (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
CN102470103B (zh) | 2009-07-07 | 2016-09-07 | 贝林格尔.英格海姆国际有限公司 | 用作丙型肝炎病毒蛋白酶抑制剂的药物组合物 |
KR20130116245A (ko) | 2010-09-30 | 2013-10-23 | 베링거 인겔하임 인터내셔날 게엠베하 | Hcv 감염 치료용 병용 요법 |
AU2011311880B2 (en) * | 2010-10-08 | 2014-07-24 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
AU2011352145A1 (en) | 2010-12-30 | 2013-07-18 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
WO2013059630A1 (en) | 2011-10-21 | 2013-04-25 | Abbvie Inc. | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
PT107924A (pt) | 2011-10-21 | 2014-12-03 | Abbvie Inc | Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv |
CN104244926A (zh) | 2012-01-12 | 2014-12-24 | 勃林格殷格翰国际有限公司 | 作为强效的hcv 抑制剂的稳定的药物制剂 |
JP2015509980A (ja) | 2012-03-14 | 2015-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Hcv−hiv同時感染患者集団のhcv感染症を治療するための併用療法 |
WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
WO2013143581A1 (en) | 2012-03-28 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in specific patient subgenotype sub-population |
WO2013169577A1 (en) * | 2012-05-07 | 2013-11-14 | Bristol-Myers Squibb Company | Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
JP6511432B2 (ja) | 2013-03-15 | 2019-05-15 | ギリアード サイエンシーズ, インコーポレイテッド | C型肝炎ウイルスの大環状二環式阻害剤 |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
WO2017062840A1 (en) * | 2015-10-09 | 2017-04-13 | Trek Therapeutics, Pbc | Combination therapy for the treatment of hepatitis c virus |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
GB0008785D0 (en) * | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
WO2003045326A2 (en) * | 2001-11-26 | 2003-06-05 | Supergen, Inc | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
CZ294371B6 (cs) * | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
RS51294B (sr) | 2003-05-21 | 2010-12-31 | Boehringer Ingelheim International Gmbh. | Inhibitorna jedinjenja za hepatitis c |
EP1753775B1 (en) * | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
-
2009
- 2009-11-18 SG SG2011036498A patent/SG171771A1/en unknown
- 2009-11-18 WO PCT/US2009/064908 patent/WO2010059667A1/en active Application Filing
- 2009-11-18 ES ES09760395.5T patent/ES2445516T3/es active Active
- 2009-11-18 ME MEP-2013-140A patent/ME01614B/me unknown
- 2009-11-18 AU AU2009316755A patent/AU2009316755B2/en not_active Expired - Fee Related
- 2009-11-18 SI SI200930810T patent/SI2358355T1/sl unknown
- 2009-11-18 DK DK09760395.5T patent/DK2358355T3/da active
- 2009-11-18 CA CA2738732A patent/CA2738732A1/en not_active Abandoned
- 2009-11-18 US US13/129,641 patent/US20120101049A1/en not_active Abandoned
- 2009-11-18 BR BRPI0921070A patent/BRPI0921070A2/pt not_active IP Right Cessation
- 2009-11-18 JP JP2011537562A patent/JP5553839B2/ja not_active Expired - Fee Related
- 2009-11-18 MY MYPI2011002269A patent/MY155402A/en unknown
- 2009-11-18 EA EA201100795A patent/EA022272B1/ru not_active IP Right Cessation
- 2009-11-18 MX MX2011005151A patent/MX2011005151A/es active IP Right Grant
- 2009-11-18 PT PT97603955T patent/PT2358355E/pt unknown
- 2009-11-18 UA UAA201107610A patent/UA105777C2/uk unknown
- 2009-11-18 PL PL09760395T patent/PL2358355T3/pl unknown
- 2009-11-18 NZ NZ592383A patent/NZ592383A/xx not_active IP Right Cessation
- 2009-11-18 KR KR1020117011446A patent/KR20110087297A/ko not_active Application Discontinuation
- 2009-11-18 PE PE2011001059A patent/PE20120032A1/es not_active Application Discontinuation
- 2009-11-18 RS RS20130583A patent/RS53121B/en unknown
- 2009-11-18 CN CN2009801464655A patent/CN102223875A/zh active Pending
- 2009-11-18 EP EP09760395.5A patent/EP2358355B1/en active Active
- 2009-11-20 UY UY0001032252A patent/UY32252A/es not_active Application Discontinuation
- 2009-11-20 TW TW98139549A patent/TWI469801B/zh not_active IP Right Cessation
- 2009-11-20 AR ARP090104496A patent/AR074391A1/es unknown
-
2011
- 2011-03-17 ZA ZA2011/02029A patent/ZA201102029B/en unknown
- 2011-03-21 IL IL211832A patent/IL211832A/en not_active IP Right Cessation
- 2011-04-19 CL CL2011000878A patent/CL2011000878A1/es unknown
- 2011-05-20 TN TN2011000258A patent/TN2011000258A1/fr unknown
- 2011-05-20 EC EC2011011065A patent/ECSP11011065A/es unknown
- 2011-05-20 MA MA33867A patent/MA32812B1/fr unknown
- 2011-05-24 CO CO11063891A patent/CO6361900A2/es not_active Application Discontinuation
-
2014
- 2014-01-24 CY CY20141100063T patent/CY1114892T1/el unknown
- 2014-02-04 HR HRP20140097AT patent/HRP20140097T1/hr unknown
- 2014-10-17 US US14/517,242 patent/US20150038532A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL211832A0 (en) | Pharmaceutical composition of a potent hcv inhibitor for oral administration | |
HK1220902A1 (zh) | 族群抑制劑之口服醫藥劑型 | |
ZA200900347B (en) | Preparation of pharmaceutical compositions | |
IL193243A0 (en) | Pharmaceutical compositions containing a thiazolidinedione derivative | |
IL218928A (en) | Corticosteroids for oral administration | |
EP2226071A4 (en) | COMPOSITIONS FOR ORAL ADMINISTRATION | |
ZA201105572B (en) | Pharmaceutical composition for oral administration | |
ZA200810178B (en) | Pharmaceutical compositions for sustained release of phenyephrine | |
EP2478904A4 (en) | PHARMACEUTICAL COMPOSITION FOR PERORAL ADMINISTRATION OF DIINDOLYLMETHANE | |
PL2387389T3 (pl) | Preparat do podawania przez śluzówkę jamy ustnej cząsteczek przeciwbólowych i/lub przeciwskurczowych | |
EP2263637A4 (en) | MEDICINAL PREPARATION FOR ORAL ADMINISTRATION | |
IL208325A0 (en) | Stabilizing lipis compositions for oral pharmaceutical agents | |
EP2407162A4 (en) | COMPOSITION FOR ORAL ADMINISTRATION | |
HK1162935A1 (en) | Pharmaceutical composition comprising a prostaglandin | |
IL208543A (en) | History of the eupyrpine peptide as potent inhibitors of encephalin-actopeptidase joint | |
ZA201102405B (en) | Pharmaceutical composition for oral administration | |
EP2520300A4 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | |
HU0900482D0 (en) | Pharmaceutical formulation for oral administration | |
HK1115054A1 (en) | Preparation for oral administration | |
PL2519261T3 (pl) | Płynna kompozycja farmaceutyczna doustna nifedypiny | |
GB0619891D0 (en) | Pharmaceutical composition of risedronate | |
IL208967A (en) | Oral Accenatide Preparations | |
IL193121A0 (en) | Pharmaceutical compositions containing a hydroxylamine derivatives |